ArticleJournal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
Use of Canine Fresh Frozen Plasma Xenotransfusions Administered to Eight Cats With Clinical Coagulopathy (2017-2024).
Article in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001). The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe a population of cats with clinical signs of coagulopathy that were treated with the administration of canine fresh frozen plasma (cFFP). A secondary objective was to assess whether cFFP xenotransfusions influenced serum total protein concentration.
designRetrospective, single-center study conducted in cats receiving cFFP xenotransfusions between 2017 and 2024.
settingPrivate referral hospital. ANIMALS: Eight privately owned cats that received cFFP xenotransfusions to treat clinical coagulopathy were identified in the electronic medical records system.
interventionsNone. MEASUREMENTS AND MAIN
resultsA search of computerized records was performed to identify feline patients that received cFFP between 2017 and 2024. Clinical notes were examined to determine the reason for and dose of cFFP xenotransfusion, the therapeutic effects of the cFFP xenotransfusions on the reported coagulopathy, and any adverse events related to transfusion. A total of eight feline patients were identified that received a total of nine cFFP xenotransfusions. The dose of cFFP administered ranged from 20 to 40 mL/kg. Seven of nine cFFP xenotransfusions (78%) resulted in successful correction of the reported coagulopathy both clinically and based on normalization of either thromboelastography or coagulation times (prothrombin and activated partial thromboplastin times). Eight of the nine cFFP xenotransfusions were well tolerated, but one recipient, which had received another cFFP transfusion within the preceding 3 months, died during the transfusion.
conclusionsAdministration of cFFP to xenotransfusion-naïve cats appeared to be well tolerated and effective in the treatment of clinical coagulopathy in this study population. Repeat cFFP xenotransfusions should be avoided, as with canine RBC xenotransfusions, but further studies are needed to more definitively assess safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.